On Monday, Prime Medicine Inc (NASDAQ: PRME) was -3.71% drop from the session before settling in for the closing price of $3.5. A 52-week range for PRME has been $1.11 – $6.94.
Healthcare Sector giant saw their annual sales slid by -124.13% over the last five years. When this article was written, the company’s average yearly earnings per share was at 19.76%. With a float of $93.82 million, this company’s outstanding shares have now reached $180.31 million.
Prime Medicine Inc (PRME) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Prime Medicine Inc stocks. The insider ownership of Prime Medicine Inc is 48.03%, while institutional ownership is 38.15%. The most recent insider transaction that took place on Aug 01 ’25, was worth 4,950,000. In this transaction 10% Owner of this company bought 1,500,000 shares at a rate of $3.30, taking the stock ownership to the 3,262,440 shares. Before that another transaction happened on Aug 01 ’25, when Company’s Director bought 3,030,300 for $3.30, making the entire transaction worth $9,999,990. This insider now owns 6,230,300 shares in total.
Prime Medicine Inc (PRME) Earnings and Forecasts
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted -0.31 earnings per share (EPS) during the time that was better than consensus figure (set at -0.31) by 0. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.24 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 19.76% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 20.13% during the next five years compared to -124.13% drop over the previous five years of trading.
Prime Medicine Inc (NASDAQ: PRME) Trading Performance Indicators
You can see what Prime Medicine Inc (PRME) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 6.61. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 101.73.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.48, a number that is poised to hit -0.25 in the next quarter and is forecasted to reach -0.93 in one year’s time.
Technical Analysis of Prime Medicine Inc (PRME)
Analysing the last 5-days average volume posted by the [Prime Medicine Inc, PRME], we can find that recorded value of 2.65 million was lower than the volume posted last year of 2.98 million. As of the previous 9 days, the stock’s Stochastic %D was 5.44%.
During the past 100 days, Prime Medicine Inc’s (PRME) raw stochastic average was set at 7.40%, which indicates a significant increase from 3.67% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.27 in the past 14 days, which was lower than the 0.39 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.10, while its 200-day Moving Average is $3.28. Now, the first resistance to watch is $3.48. This is followed by the second major resistance level at $3.58. The third major resistance level sits at $3.66. If the price goes on to break the first support level at $3.30, it is likely to go to the next support level at $3.22. Should the price break the second support level, the third support level stands at $3.12.
Prime Medicine Inc (NASDAQ: PRME) Key Stats
There are 180,511K outstanding shares of the company, which has a market capitalization of 608.32 million. As of now, sales total 2,980 K while income totals -195,880 K. Its latest quarter income was 1,230 K while its last quarter net income were -50,580 K.
